Innovent, Lilly Obesity Drug Spurs More Weight Loss in Trial
- Company to start final-stage study of mazdutide this year
- Innovent is developing the obesity drug with Eli Lilly
This article is for subscribers only.
Innovent Biologics Inc.’s obesity drug mazdutide continued to help people shed pounds for almost a year in a mid-stage study in China, yielding an average 18.6% of body weight lost after 48 weeks.
The drug, in development with Eli Lilly & Co., will be studied in a late-stage trial that will start this year, Innovent said Sunday in a statement. Participants initially lost 15% of their body weight — or 14.7 kilograms (32.4 pounds) on average — after 24 weeks’ treatment, results reported in May showed. Those who continued taking a weekly 9 milligram dose for a further 24 weeks eventually shed 19% of their body weight, or 17.8 kilograms on average.